Search Results - "Becourt, C."

Refine Results
  1. 1

    Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy by Bécourt, C., Marguet, C., Balguerie, X., Joly, P.

    Published in British journal of dermatology (1951) (01-10-2013)
    “…Summary Background The incidence of scabies is increasing in Europe, and it often affects children and infants. Although numerous topical treatments have been…”
    Get full text
    Journal Article
  2. 2

    The targeting of β-cells by T lymphocytes in human type 1 diabetes: clinical perspectives by Luce, S., Briet, C., Bécourt, C., Lemonnier, F., Boitard, C.

    Published in Diabetes, obesity & metabolism (01-09-2013)
    “…This review focuses on genes that control β‐cell targeting in autoimmune, type 1‐dependent, diabetes (T1D) and on insulin as the major autoantigen recognized…”
    Get full text
    Journal Article
  3. 3

    Pancreatic islet beta cells drive T cell-immune responses in the nonobese diabetic mouse model by Larger, E, Bécourt, C, Bach, J F, Boitard, C

    Published in The Journal of experimental medicine (01-05-1995)
    “…The role of autoantigens and that of target organs in which tissue lesions develop remains elusive in most spontaneous models of autoimmune diseases. Whether…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Peripherin: An Islet Antigen that is Cross-Reactive with Nonobese Diabetic Mouse Class II Gene Products by Boitard, C., Villa, M. C., Becourt, C., Gia, H. Pham, Huc, C., Sempe, P., Portier, M. M., Bach, J. F.

    “…The nonobese diabetic (NOD) mouse, in which major histocompatibility complex genes may be involved in the susceptibility to diabetes, has been developed as a…”
    Get full text
    Journal Article
  7. 7

    The targeting of [beta]-cells by T lymphocytes in human type 1 diabetes: clinical perspectives by Luce, S, Briet, C, Becourt, C, Lemonnier, F, Boitard, C

    Published in Diabetes, obesity & metabolism (01-09-2013)
    “…This review focuses on genes that control [beta]-cell targeting in autoimmune, type 1-dependent, diabetes (T1D) and on insulin as the major autoantigen…”
    Get full text
    Journal Article
  8. 8

    Peripheral CD8+CD25+ T Lymphocytes from MHC Class II-Deficient Mice Exhibit Regulatory Activity by Bienvenu, Boris, Martin, Bruno, Auffray, Cedric, Cordier, Corinne, Becourt, Chantal, Lucas, Bruno

    Published in The Journal of immunology (1950) (01-07-2005)
    “…We characterized CD8(+) T cells constitutively expressing CD25 in mice lacking the expression of MHC class II molecules. We showed that these cells are present…”
    Get full text
    Journal Article
  9. 9

    Suppression of CD4+ T Lymphocyte Effector Functions by CD4+CD25+ Cells In Vivo by Martin, Bruno, Banz, Alice, Bienvenu, Boris, Cordier, Corinne, Dautigny, Nicole, Becourt, Chantal, Lucas, Bruno

    Published in The Journal of immunology (1950) (15-03-2004)
    “…CD4+CD25+ regulatory T cells have been extensively studied during the last decade, but how these cells exert their regulatory function on pathogenic effector T…”
    Get full text
    Journal Article
  10. 10

    T Cell Response to Preproinsulin I and II in the Nonobese Diabetic Mouse by Halbout, Philippe, Briand, Jean-Paul, Becourt, Chantal, Muller, Sylviane, Boitard, Christian

    Published in The Journal of immunology (1950) (01-09-2002)
    “…Immunization against insulin, insulin B chain, or B chain peptide B(9-23) (preproinsulin peptide II(33-47)) prevents diabetes in the nonobese diabetic (NOD)…”
    Get full text
    Journal Article
  11. 11

    Suppression of CD4 super(+) T Lymphocyte Effector Functions by CD4 super(+)CD25 super(+) Cells In Vivo by Martin, B, Banz, A, Bienvenu, B, Cordier, C, Dautigny, N, Becourt, C, Lucas, B

    Published in The Journal of immunology (1950) (01-03-2004)
    “…CD4 super(+)CD25 super(+) regulatory T cells have been extensively studied during the last decade, but how these cells exert their regulatory function on…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Origin of the beta cells of the islets of Langerhans is further questioned by the expression of neuronal intermediate filament proteins, peripherin and NF-L, in the rat insulinoma RIN5F cell line by Escurat, M, Djabali, K, Huc, C, Landon, F, Bécourt, C, Boitard, C, Gros, F, Portier, M M

    Published in Developmental neuroscience (1991)
    “…Intermediate filament proteins of the rat insulinoma RIN5F cell line were characterized. Two-dimensional gel analysis followed by immunostaining of proteins…”
    Get more information
    Journal Article
  14. 14

    Pyoderma gangrenosum induit par l’azacitidine dans un contexte de syndrome myélodysplasique by Marcant, P., Terrom, M., Alsuliman, T., Choufi, B., Le Moing, A., Bécourt, C., Delforge, A.-F., Darras, S.

    “…Le pyoderma gangrenosum est une maladie neutrophilique révélant souvent une pathologie systémique, notamment hématologique, et classiquement majoré par les…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Les manifestations cutanées des histiocytoses langerhansiennes de l’enfant : une étude rétrospective de 24 ans by Bellissen, A., Bécourt, C., Buche, S., Lambilliotte, A., Catteau, B.

    “…L’histiocytose langerhansienne (HL) est une maladie rare caractérisée par une prolifération clonale de cellules de Langerhans. L’objectif principal de l’étude…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Autoantibodies against pancreatic beta-cells: characterization by western blot analysis in the non-obese diabetic (NOD) mouse by Villà, M C, Bécourt, C, Gia, H P, Sempé, P, Portier, M M, Bach, J F, Boitard, C

    Published in Journal of autoimmunity (01-02-1992)
    “…The NOD mouse is a relevant model for studying autoimmune diabetes. As in human insulin-dependent diabetes mellitus, the nature of the autoantigen towards…”
    Get more information
    Journal Article
  19. 19

    Interaction du dabrafénib avec les immunosuppresseurs by Levavasseur, M., Darras-Vercambre, S., Mortier, L., Céline, G., Le Moing, A., Bécourt, C., Auffret, M., Gautier, S., Bertrand, M.

    “…Le dabrafénib est un inhibiteur de BRAF indiqué en monothérapie dans le traitement des patients adultes atteints d’un mélanome non résécable ou métastatique…”
    Get full text
    Journal Article
  20. 20